25E-NB3OMe

25E-NB3OMe is a synthetic psychedelic compound that belongs to the NBOMe class of drugs. It is a derivative of the phenethylamine 2C-E and is known for its potent hallucinogenic effects. The compound is part of a larger group of substances that have been used in research settings to study the effects of psychedelics on the human brain.

Chemical Structure and Properties

25E-NB3OMe is chemically related to the 2C family of phenethylamines, specifically 2C-E. The NBOMe series is characterized by the addition of a 2-methoxybenzyl (NB) group to the nitrogen atom of the phenethylamine backbone. This modification significantly increases the compound's affinity for the 5-HT2A receptor, which is primarily responsible for its psychedelic effects.

The full chemical name of 25E-NB3OMe is 2-(4-ethoxy-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine. The presence of the ethoxy group at the 4-position of the phenyl ring distinguishes it from other NBOMe compounds.

Pharmacology

25E-NB3OMe acts as a potent agonist at the 5-HT2A receptor, which is a subtype of the serotonin receptor family. Activation of this receptor is known to produce psychedelic effects, including altered perception, mood, and cognition. The compound's high affinity for the 5-HT2A receptor makes it significantly more potent than its parent compound, 2C-E.

Effects

The effects of 25E-NB3OMe are similar to those of other psychedelics, such as LSD and psilocybin. Users report visual hallucinations, changes in thought patterns, and an altered sense of time. The onset of effects typically occurs within 30 to 90 minutes after ingestion, with the peak lasting several hours.

Risks and Safety

Due to its potency, 25E-NB3OMe carries a risk of overdose, which can lead to severe adverse effects, including vasoconstriction, hypertension, and tachycardia. There have been reports of fatalities associated with the use of NBOMe compounds, often due to misidentification or improper dosing.

Legal Status

The legal status of 25E-NB3OMe varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. Researchers must obtain special licenses to study the compound in a laboratory setting.

Research

Research on 25E-NB3OMe and related compounds is ongoing, with studies focusing on their pharmacological properties, potential therapeutic uses, and the mechanisms underlying their psychedelic effects. These studies contribute to a broader understanding of the role of serotonin receptors in the brain.

Also see

• NBOMe series
• 2C-E
• Psychedelic research
• Serotonin receptor
• Hallucinogen